Abstract 2575: EZH2 mediates resistance to cisplatin in small cell lung cancer through nucleotide excision repair

Volume: 79, Pages: 2575 - 2575
Published: Jul 1, 2019
Abstract
Small cell lung cancer (SCLC) is the most aggressive form of lung cancer, with a five-year survival rate of 7%. Cisplatin-based chemotherapy is the first line treatment for SCLC; however, many patients develop treatment resistance and experience tumor recurrence. Targeting proteins critical to the repair of cisplatin DNA crosslinks is a strategy for overcoming acquired cisplatin resistance in SCLC, but many proteins that mediate crosslink repair...
Paper Details
Title
Abstract 2575: EZH2 mediates resistance to cisplatin in small cell lung cancer through nucleotide excision repair
Published Date
Jul 1, 2019
Volume
79
Pages
2575 - 2575
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.